Plasma and intrapulmonary population pharmacokinetics of piperacillin/tazobactam in critically ill patients - PROPE

niversity Hospital of South Manchester0 个研究点目标入组 40 人开始时间: 2011年9月21日最近更新: 2019年11月25日

试验速览

暂无简介。

•1.Subject is an adult aged 18 to 85
•2.Subject requires or has been commenced on piperacillin/tazobactam as directed by clinical Intensive Care Unit medical staff
•Are the trial subjects under 18? no
•Number of subjects for this age range: 0
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 30
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 10

•1.Subject is known to be intolerant of ß-lactams antibiotics
•2.Subject has an infection with a piperacillin/tazobactam resistant organism (i.e. P. aeruginosa with MIC =16 mg/L, other organism with MIC = 8mg/L) or organisms with inherent resistance (e.g. Stenotrophomonas)
•3.Subject is immunocompromised (neutropenia, HIV/AIDS)
•4.Subject is unlikely to survive longer the 48 hours
•5.Subject is pregnant or breast-feeding or plans to become pregnant during the course of the study
•6.Subject is enrolled in another Clinical Trial of an Investigational Medical Product.

发起方

niversity Hospital of South Manchester